Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Meeting of Stockholders on May 24, 2017. The following is a
summary of the matters voted on at that meeting.
|
1.
|
The Companys stockholders elected Richard H. Aldrich,
Thomas G. Auchincloss, Jr. and Christine van Heek as class III directors to serve until the 2020 Annual Meeting of Stockholders, each such director to hold office until his or her successor has been duly elected and qualified. The results of the stockholders vote with respect to the election of such class III directors were as follows: |
|
Votes For
|
Votes
Withheld
|
Broker
Non-Votes
|
||||
|
Richard H. Aldrich
|
13,539,609
|
3,870,646
|
3,604,926
|
|||
|
Thomas G. Auchincloss, Jr.
|
14,892,135
|
2,518,120
|
3,604,926
|
|||
|
Christine van Heek
|
14,892,045
|
2,518,210
|
3,604,926
|
|
2.
|
The Companys stockholders ratified the appointment of
Ernst Young LLP as the Companys independent registered public accounting firm for the current fiscal year. The results of the stockholders vote with respect to such ratification were as follows: |
|
Votes For
|
Votes
Against
|
Votes
Abstaining
|
||
|
20,986,614
|
14,914
|
13,653
|
|
3.
|
The Companys stockholders authorized the sale of the
clinical candidate CTP-656 and other assets related to the treatment of cystic fibrosis by the Company to Vertex Pharmaceuticals. |
|
Votes For
|
Votes
Against
|
Votes
Abstaining
|
Broker Non-Votes
|
|||
|
17,314,969
|
15,594
|
76,692
|
3,604,926
|
About Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company’s product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Recent Trading Information
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) closed its last trading session down -0.08 at 14.16 with 367,137 shares trading hands.
